Avalo Therapeutics Inc. (NASDAQ: AVTX)
$12.40
-0.2500 ( -1.98% ) 2.4K
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Market Data
Open
$12.40
Previous close
$12.65
Volume
2.4K
Market cap
$13.03M
Day range
$11.96 - $13.17
52 week range
$3.95 - $84.79
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 67 | Nov 09, 2023 |
8-k | 8K-related | 14 | Nov 09, 2023 |
8-k | 8K-related | 14 | Oct 31, 2023 |
ars | Annual reports | 1 | Oct 19, 2023 |
def | Proxies and info statements | 6 | Oct 19, 2023 |
8-k | 8K-related | 13 | Oct 17, 2023 |
pre | Proxies and info statements | 6 | Oct 05, 2023 |
8-k | 8K-related | 12 | Oct 03, 2023 |
8-k | 8K-related | 16 | Sep 26, 2023 |
8-k | 8K-related | 12 | Sep 13, 2023 |